
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
 Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 Definitive Proxy Statement
 Definitive Additional Materials
 Soliciting Material under §240.14a-12

OncoSec Medical Incorporated

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
 Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

Facebook:

1. OncoSec announces that shareholders have approved the CGP/Sirtex Transaction. Read our latest press release on our website: <https://advancingoncosec.com/> / <https://advancingoncosec.com/materials-for-investors/>
2. OncoSec's shareholders approved the CGP/Sirtex Transaction! Dan O'Connor, President and Chief Executive Officer of OncoSec, said, "I personally would like to thank all of our shareholders for making their voices heard at this Special Meeting and for their support for the CGP/Sirtex Transaction. This Transaction marks the start of a collaboration with CGP and Sirtex, two powerful drug development companies, which we expect will flourish over time." Read our latest press release on our website: <https://advancingoncosec.com/> / <https://advancingoncosec.com/materials-for-investors/> / <https://advancingoncosec.com/proxy-legend/>

LinkedIn:

1. OncoSec announces that shareholders have approved the CGP/Sirtex Transaction. Read our latest press release on our website: <https://lnkd.in/gZYYKNM/> / https://lnkd.in/er9_vzH
2. OncoSec's shareholders approved the CGP/Sirtex Transaction! Dan O'Connor, President and Chief Executive Officer of OncoSec, said, "I personally would like to thank all of our shareholders for making their voices heard at this Special Meeting and for their support for the CGP/Sirtex Transaction. This Transaction marks the start of a collaboration with CGP and Sirtex, two powerful drug development companies, which we expect will flourish over time." Read our latest press release on our website: <https://lnkd.in/gZYYKNM/> / https://lnkd.in/er9_vzH / <https://lnkd.in/g3Z6jib>

Twitter:

1. \$ONCS shareholders approved the CGP/Sirtex Transaction. Read OncoSec's press release on our website: <https://advancingoncosec.com/> / <https://advancingoncosec.com/materials-for-investors/>
 2. Thank you \$ONCS shareholders for approving the CGP/Sirtex Transaction. Read OncoSec's press release on our website: <https://advancingoncosec.com/> / <https://advancingoncosec.com/materials-for-investors/>
-

